Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma - Response

被引：0
|
作者：
Saad, F [1 ]
机构：
[1] CHU Montreal, Hop Notre Dame de Bon Secours, Urooncol Clin, Montreal, PQ H2L 4M1, Canada
来源：
JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2003年 / 95卷 / 15期
关键词：
D O I：
10.1093/jnci/djg021
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
下载
收藏
页码：1175 / 1175
页数：1
相关论文
共 50 条
  • [31] Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC)
    Kattan, Joseph G.
    Farhat, Fady S.
    Chahine, Georges Y.
    Nasr, Fady L.
    Moukadem, Walid T.
    Younes, Fariha C.
    Yazbeck, Nadine J.
    Ghosn, Marwan G.
    INVESTIGATIONAL NEW DRUGS, 2008, 26 (01) : 75 - 79
  • [32] Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC)
    Joseph G. Kattan
    Fady S. Farhat
    Georges Y. Chahine
    Fady L. Nasr
    Walid T. Moukadem
    Fariha C. Younes
    Nadine J. Yazbeck
    Marwan G. Ghosn
    Investigational New Drugs, 2008, 26 : 75 - 79
  • [33] Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma
    Morant, R
    Bernhard, J
    Maibach, R
    Borner, M
    Fey, MF
    Thürlimann, B
    Jacky, E
    Trinkler, F
    Bauer, J
    Zulian, G
    Hanselmann, S
    Hürny, C
    Hering, F
    ANNALS OF ONCOLOGY, 2000, 11 (02) : 183 - 188
  • [34] Osteonecrosis of jaw in patient with hormone-refractory prostate cancer treated with zoledronic acid
    Olson, KB
    Hellie, CM
    Pienta, KJ
    UROLOGY, 2005, 66 (03) : 658E1 - 658E3
  • [35] New hope for patients with metastatic hormone-refractory prostate cancer
    de Wit, Ronald
    EUROPEAN UROLOGY SUPPLEMENTS, 2006, 5 (15) : 817 - 823
  • [36] Placebo-controlled, randomized, phase II study of radium-223 in metastatic hormone refractory prostate cancer (HRPC)
    Nilsson, S.
    Franzen, L.
    Tyrrel, C.
    Blom, R.
    Tennvall, J.
    Lennernas, B.
    Johannessen, D. C.
    Sokal, M.
    Parker, C.
    Bruland, O. S.
    EJC SUPPLEMENTS, 2007, 5 (04): : 295 - 295
  • [37] EFFICACY AND SAFETY OF THE ASSOCIATION OF PACLITAXEL AND ESTRAMUSTINE WITH ZOLENDRONIC ACID, IN METASTATIC HORMONE-REFRACTORY PROSTATE CARCINOMA
    Chiesa, M. Dalla
    Negri, F.
    Bergonzi, C.
    Musolino, A.
    Perrone, A.
    Potenzoni, D.
    Cantoni, C.
    Di Giovanni, M.
    Donati, G. V.
    Passalacqua, R.
    ANNALS OF ONCOLOGY, 2004, 15 : 97 - 97
  • [38] Docetaxel, vinorelbine and zoledronic acid as first-line treatment in patients with hormone-refractory prostate cancer
    不详
    EUROPEAN UROLOGY SUPPLEMENTS, 2006, 5 (02) : 95 - 95
  • [39] The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid
    Oh, William K.
    Proctor, Kevin
    Nakabayashi, Mari
    Evan, Carolyn
    Tormey, Lauren K.
    Daskivich, Timothy
    Antras, Lucia
    Smith, Michael
    Neary, Maureen P.
    Duh, Mei Sheng
    CANCER, 2007, 109 (06) : 1090 - 1096
  • [40] Economic Evaluation of Denosumab Compared with Zoledronic Acid in Hormone-Refractory Prostate Cancer Patients with Bone Metastases
    Rader, Michael
    Goessl, Carsten
    Cong, Ze
    JOURNAL OF MANAGED CARE PHARMACY, 2012, 18 (01): : 74 - 75
12345